Harm HogenEsch
· Distinguished Professor of ImmunopathologyPurdue University · Pathobiology
Active 1987–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Dr. Harm HogenEsch is a Distinguished Professor of Immunopathology in the Department of Comparative Pathobiology at the College of Veterinary Medicine, Purdue University. He grew up in the Netherlands and earned his Doctor of Veterinary Medicine (DVM) degree cum laude from the University of Utrecht in 1984. He pursued graduate training in immunology at the University of Illinois at Urbana-Champaign under the mentorship of Dr. Peter Felsburg, receiving his PhD in 1989. Dr. HogenEsch is board-certified by the American College of Veterinary Pathologists since 1989. After working as a staff scientist at the TNO Institute for Aging and Vascular Research in Leiden, the Netherlands, he joined Purdue University in 1993 and was promoted to Professor in 2001. Dr. HogenEsch has made significant contributions to veterinary immunopathology, with over 140 peer-reviewed journal articles and 18 book chapters published. He has trained 18 graduate students and postdoctoral fellows, reflecting his commitment to education and research mentorship. His research group focuses on vaccine development and adjuvants, as well as immunological mechanisms related to diseases such as atopic dermatitis. His work advances understanding of immune responses and the design of vaccines, contributing to both veterinary and translational immunology.
Research topics
- Biology
- Immunology
- Medicine
- Internal medicine
- Virology
- Materials science
- Biochemical engineering
- Engineering
- Biochemistry
- Nanotechnology
Selected publications
Aluminum Adjuvants—‘Back to the Future’
Pharmaceutics · 2023 · 76 citations
Aluminum-based adjuvants will continue to be a key component of currently approved and next generation vaccines, including important combination vaccines. The widespread use of aluminum adjuvants is due to their excellent safety profile, which has been established through the use of hundreds of millions of doses in humans over many years. In addition, they are inexpensive, readily available, and are well known and generally accepted by regulatory agencies. Moreover, they offer a very flexible pl…
Vaccines · 2020 · 32 citations
Intranasal vaccination elicits secretory IgA (SIgA) antibodies in the airways, which is required for cross-protection against influenza. To enhance the breadth of immunity induced by a killed swine influenza virus antigen (KAg) or conserved T cell and B cell peptides, we adsorbed the antigens together with the TLR3 agonist poly(I:C) electrostatically onto cationic alpha-D-glucan nanoparticles (Nano-11) resulting in Nano-11-KAg-poly(I:C) and Nano-11-peptides-poly(I:C) vaccines. In vitro, increase…
The Journal of Immunology · 2020 · 28 citations
Senior authorCorrespondingIntradermal (ID) immunization is an attractive route of vaccination because it targets tissue rich in dendritic cells, has dose-sparing potential, and allows needle-free delivery. However, few adjuvants are effective, nonreactogenic, and compatible with needle-free delivery devices. In this study, we demonstrate that a combination adjuvant composed of cyclic-di-AMP (cdAMP) and the plant-derived nanoparticle adjuvant Nano-11 significantly enhanced the immune response to ID-injected vaccines in mi…
Local and Systemic Changes in Lipid Profile as Potential Biomarkers for Canine Atopic Dermatitis
Metabolites · 2021 · 14 citations
Senior authorCorrespondingLipids play a critical role in the skin as components of the epidermal barrier and as signaling and antimicrobial molecules. Atopic dermatitis in dogs is associated with changes in the lipid composition of the skin, but whether these precede or follow the onset of dermatitis is unclear. We applied rapid lipid-profiling mass spectrometry to skin and blood of 30 control and 30 atopic dogs. Marked differences in lipid profiles were observed between control, nonlesional, and lesional skin. The lipid…
Vaccines · 2023-11-07 · 9 citations
articleOpen accessSenior authorCorrespondingThe development of cross-protective vaccines against the zoonotic swine influenza A virus (swIAV), a potential pandemic-causing agent, continues to be an urgent global health concern. Commercially available vaccines provide suboptimal cross-protection against circulating subtypes of swIAV, which can lead to worldwide economic losses and poor zoonosis deterrence. The limited efficacy of current swIAV vaccines demands innovative strategies for the development of next-generation vaccines. Consideri…
Recent grants
NIH · $5.9M · 2018
Frequent coauthors
- 36 shared
John P. Sundberg
- 23 shared
Briän Catchpole
Royal Veterinary College
- 19 shared
Stanley L. Hem
- 14 shared
Anna Sokolovska
- 13 shared
Juan F. Hernandez-Franco
Purdue University West Lafayette
- 12 shared
Gourapura J. Renukaradhya
- 12 shared
Fangjia Lu
Purdue University West Lafayette
- 12 shared
Peter J. Felsburg
University of Pennsylvania
Education
- 1989
Ph.D., Pathobiology
University of Illinois
- 1984
DVM, College of Veterinary Medicine
University of Utrecht, Netherlands
Similar researchers at Purdue University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Harm HogenEsch
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup